
Catch up on the most impactful headlines in cardiology from all of 2025 with our Year in Review.

Catch up on the most impactful headlines in cardiology from all of 2025 with our Year in Review.

Clinicians across specialties explain how health misinformation is reshaping patient decisions, delaying care, and undermining trust.

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.


Explore the critical role of nutrition and pharmacologic therapies in managing hypertriglyceridemia and preventing pancreatitis effectively.

Explore how the latest FDA approvals impact the management of FCS.

Panelists break down the potential role of plozasiran in FCS based on the PALISADE trial.

Understanding severe hypertriglyceridemia is crucial for preventing pancreatitis and managing triglyceride levels effectively.

Discover effective strategies to shorten the diagnostic window for pancreatitis and manage high triglyceride levels in FCS.

Explore the challenges and advancements in managing FCS with expert insights on treatment and patient care.

Le discusses the increased risk of mortality and major adverse cardiovascular events in patients with both PAD and AF.

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.

This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.

Read about hepatic FDA news, the voluntary withdrawal of obeticholic acid for PBC, new trial data for a potential AATD drug, and more.

Le discusses methods by which clinicians can ease the financial burden of obtaining and adhering to medication for their patients.

Le describes growing multidisciplinary conversations around CKM and why cardiovascular health needs to be a central focus of MASH/MASLD care.

Le discusses the implications of these new guidelines and whether the US healthcare system can manage the increasing public burden of hypertension.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.

Viet Le, PA-C, DMSc, breaks down new data and updates from AHA 24, spotlighting 3 specific trials and the applicability of artificial intelligence in care.

Laura Ross, PA-C, shares insights from the inaugural CAPP meeting on how lifestyle medicine and targeted therapies are transforming cardiovascular care.

Past APAC President Viet Le shares insights from CAPP 2024 on managing high-risk ASCVD, new non-statin therapies, and options for statin-intolerant patients.

In this episode, John Giacona, PhD, PA-C, shares insights from the 2024 AHA Hypertension Scientific Sessions, focusing on primary aldosteronism and renal denervation.

In this edition of the APAC Recap, Erin Pardee, PA-C, discusses the American Society of Preventive Cardiology 2024 Congress on CVD Prevention with Viet Le, DMSc, PA-C.

The APAC Recap is a new multimedia series created through a partnership between APAC and HCPLive where members of the Academy of Physician Associates have peer-to-peer discussions centered around recent scientific congresses and meetings.

Laura Ross, PA-C, sits down for a Q&A on the HeartBeet Clinic and the role of reimbursable group visits in cardiovascular disease management and education.

Join us April 01 on Twitter for a pre-meeting Tweet chat ahead of the American College of Cardiology's 2024 annual meeting!

In recognition of 60 years since the historic contribution to modern understanding of the harmful effects of cigarette smoking, Albert Rizzo, MD, meets with the preventive cardiology expert to discuss the myriad of cascading effects delivered by the 1964 report.

New research from Intermountain Healthcare presented at ACC 2023 examines the prognostic value of disproportionate CAC scores for 1 or more vessels relative to the value of total CAC score for predicting major adverse cardiovascular events.

Viet Le, PA-C, offers perspective on a study from Intermountain Healthcare reporting on the epidemiology, relationship to ASCVD risk factors, and clinical outcomes associated with Lp(a) in real-world settings.